UroosaIbrahimMD
Hematology • New York, NYHematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Physician
Dr. Ibrahim is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Gustave L. Levy Pl
New York, NY 10029
Education & Training
Ziauddin Medical UniversityClass of 2009
Certifications & Licensure
NY State Medical License 2015 - 2026
NJ State Medical License 2018 - 2019- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903 Start of enrollment: 2021 Oct 25
Roles: Contact
Publications & Presentations
PubMed
- 10 citationsCheckpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.Sanjal H Desai, Michael A Spinner, Kevin David, Veronika Bachanova, Gaurav Goyal
American Journal of Hematology. 2023-03-01 - 48 citationsCOVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter.Ankur Varma, Satyajit Kosuri, Celalettin Ustun, Uroosa Ibrahim, Jonathan Moreira
Leukemia. 2020-08-14 - 9 citationsReal-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD.Marshall McKenna, Narendranath Epperla, Armin Ghobadi, Jieqi Liu, Aleksandr Lazaryan
British Journal of Haematology. 2023-07-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
